LabCorp Announces 2019 Third Quarter Results and Updates 2019 Guidance

Q3 revenue of $2.9 billion , up 3.4% over $2.8 billion last year Q3 diluted EPS of $2.25 , down from $3.10 last year, which included the net gain on the disposition of the Food Solutions business of $1.22 per share Q3 adjusted EPS of $2.90 , up 5.8% over $2.74 last year Q3 free cash flow of $363

LabCorp Expands Services in Northwest Indiana and Surrounding Region Through Acquisition of Diagnostic Clinical Laboratory Assets From South Bend Medical Foundation

 South Bend Medical Foundation and LabCorp Also Establish Pathology Services Collaboration to Serve Customers and Patients Across Four States BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 22, 2019-- LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient

HealthEC, LabCorp, and The New Jersey Primary Care Association Announce Strategic Collaboration to Advance Value-Based Care at Community Health Centers

Agreement Establishes Database and Information Exchange Platform to Facilitate Care-Delivery Collaboration Between Participating New Jersey FQHCs Through LabCorp’s Care Intelligence Module BURLINGTON, N.C. & EDISON, N.J. & HAMILTON, N.J. --(BUSINESS WIRE)--Oct.

LabCorp Celebrates 50 Years of Improving Health, Improving Lives

BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 15, 2019-- LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced that it will mark its 50th anniversary at a celebration Oct. 15 in Burlington, North Carolina , where the company has

Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C. --(BUSINESS WIRE)--Oct. 14, 2019-- LabCorp® (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject

LabCorp Announces New Leadership Roles for Its Two Business Segments and Selects New Chief Human Resources Officer

    John Ratliff , current CEO of Covance, to become CEO of LabCorp Diagnostics   Dr. Paul Kirchgraber , current senior vice president and head of Covance’s clinical trial testing solutions, to become CEO of Covance   Both business segment CEO roles are effective Nov. 1 when Adam H.

LabCorp Publishes Largest Study to Date on Prenatal Cell-Free DNA Screenings in Multifetal Pregnancies

Study of nearly 30,000 cases finds that non-invasive cfDNA screening for fetal aneuploidy in pregnancies with twins, triplets, and higher-order multiples meets or exceeds performance of singleton pregnancy screening   BURLINGTON, N.C. --(BUSINESS WIRE)--Sep.

LabCorp to Announce Third Quarter Financial Results on October 24, 2019

  BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 24, 2019-- LabCorp® (NYSE: LH) will release its third quarter of 2019 financial results before the market opens on Thursday, Oct. 24, 2019 , followed by a conference call and webcast beginning at 9:00 a.m. EDT to discuss the results.

LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 To Accrue Contingent Interest

BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 11, 2019-- LabCorp® (NYSE: LH) announced today that for the period of Sept. 11, 2019 to March 10, 2020 , its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will, subject to the terms of the Zero Coupon Notes, accrue contingent cash

Covance Unveils New R&D Center in Shanghai

Inauguration Ceremony Highlights World-Class, Comprehensive Drug Development Capabilities and More Than Two Decades of Growth in China BURLINGTON, N.C. --(BUSINESS WIRE)--Sep. 10, 2019-- LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care,